P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease

Neurobiology of Disease

Volumn 45, Issue 3, 2012, Pages 999-1009

  Fan, Jing ^a,b   Gladding, Clare M ^a,b   Wang, Liang ^a,b   Zhang, Lily Y J ^a,b   Kaufman, Alexandra M ^a,b   Milnerwood, Austen J ^a,b   Raymond, Lynn A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Excitotoxicity; Huntington disease; JNK; NMDA receptor; P38; PSD 95

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; POLYGLUTAMINE; POSTSYNAPTIC DENSITY PROTEIN 95; STRESS ACTIVATED PROTEIN KINASE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITOTOXICITY; HUNTINGTON CHOREA; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SPINAL CORD NERVE CELL; TISSUE DISTRIBUTION; WILD TYPE; YEAST ARTIFICIAL CHROMOSOME;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BACTERIAL PROTEINS; CEREBRAL CORTEX; CHROMOSOMES, ARTIFICIAL, YEAST; COCULTURE TECHNIQUES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GUANYLATE KINASE; HUMANS; HUNTINGTON DISEASE; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; LUMINESCENT PROTEINS; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; RECEPTORS, N-METHYL-D-ASPARTATE; SUBCELLULAR FRACTIONS;

EID: 84856579300     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.019     Document Type: Article

References (93)

1. Aarts M., et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002, 298:846-850.
2. Barria A., Malinow R. Subunit-specific NMDA receptor trafficking to synapses. Neuron 2002, 35:345-353.
3. Bezprozvanny I., Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 2004, 322:1310-1317.
4. Bossy-Wetzel E., et al. Molecular pathways to neurodegeneration. Nat. Med. 2004, 10(Suppl.):S2-S9.
5. Boulanger L.M., et al. Cellular and molecular characterization of a brain-enriched protein tyrosine phosphatase. J. Neurosci. 1995, 15:1532-1544.
6. Braithwaite S.P., et al. Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP). Eur. J. Neurosci. 2006, 23:2847-2856.
7. Braithwaite S.P., et al. Synaptic plasticity: one STEP at a time. Trends Neurosci. 2006, 29:452-458.
8. Cao J., et al. The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J. Cell Biol. 2005, 168:117-126.
9. Cattaneo E., Calabresi P. Mutant huntingtin goes straight to the heart. Nat. Neurosci. 2002, 5:711-712.
10. Chen N., et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 1999, 72:1890-1898.
11. Chen Q., et al. Differential roles of NR2A- and NR2B-containing NMDA receptors in activity-dependent brain-derived neurotrophic factor gene regulation and limbic epileptogenesis. J. Neurosci. 2007, 27:542-552.
12. Christie J.M., et al. Native N-methyl-d-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J. Pharmacol. Exp. Ther. 2000, 292:1169-1174.
13. Coffey E.T., et al. c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J. Neurosci. 2002, 22:4335-4345.
14. Cowan C.M., Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol. 2006, 75:25-71.
15. Cowan C.M., et al. Polyglutamine-modulated striatal calpain activity in YAC transgenic Huntington disease mouse model: impact on NMDA receptor function and toxicity. J. Neurosci. 2008, 28:12725-12735.
16. Diamond J.S. A broad view of glutamate spillover. Nat. Neurosci. 2002, 5:291-292.
17. Dick O., Bading H. Synaptic activity and nuclear calcium signaling protect hippocampal neurons from death signal-associated nuclear translocation of FoxO3a induced by extrasynaptic N-methyl-d-aspartate receptors. J. Biol. Chem. 2010, 285:19354-19361.
18. Fan M.M., et al. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 27:3768-3779.
19. Fan J., et al. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J. Neurosci. 2009, 29:10928-10938.
20. Fan J., et al. N-methyl-d-aspartate receptor subunit- and neuronal-type dependence of excitotoxic signaling through post-synaptic density 95. J. Neurochem. 2010, 115:1045-1056.
21. Fernandes H.B., et al. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci. 2007, 27:13614-13623.
22. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J. Neurosci. 2002, 22:4842-4849.
23. Gafni J., et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 2004, 279:20211-20220.
24. Ghatan S., et al. p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J. Cell Biol. 2000, 150:335-347.
25. Gianfriddo M., et al. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol. Dis. 2004, 17:77-88.
26. Graham R.K., et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis. 2006, 21:444-455.
27. Haddad J.J. N-methyl-d-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: a revolving neurochemical axis for therapeutic intervention?. Prog. Neurobiol. 2005, 77:252-282.
28. Hardingham G.E. Pro-survival signalling from the NMDA receptor. Biochem. Soc. Trans. 2006, 34:936-938.
29. Hardingham G.E., Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003, 26:81-89.
30. Harper S.J., Wilkie N. MAPKs: new targets for neurodegeneration. Expert Opin. Ther. Targets 2003, 7:187-200.
31. Heng M.Y., et al. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 2009, 29:3200-3205.
32. Hodgson J.G., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
33. Hsieh C.C., Papaconstantinou J. The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid. Mech. Ageing Dev. 2002, 123:1423-1435.
34. Hsieh C.C., et al. Age-associated changes in SAPK/JNK and p38 MAPK signaling in response to the generation of ROS by 3-nitropropionic acid. Mech. Ageing Dev. 2003, 124:733-746.
35. Izumi Y., et al. Long-term potentiation inhibition by low-level N-methyl-d-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus 2008, 18:258-265.
36. Jarabek B.R., et al. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004, 127:505-516.
37. Juo P., et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol. 1997, 17:24-35.
38. Kaech S., Banker G. Culturing hippocampal neurons. Nat. Protoc. 2006, 1:2406-2415.
39. Kawasaki H., et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem. 1997, 272:18518-18521.
40. Kim J.H., et al. SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 protein family. Neuron 1998, 20:683-691.
41. Kulisz A., et al. Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 282:L1324-L1329.
42. Landwehrmeyer G.B., et al. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 1995, 15:5297-5307.
43. Leavitt B.R., et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 2001, 68:313-324.
44. Leveille F., et al. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008, 22:4258-4271.
45. Levine M.S., et al. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 1999, 58:515-532.
46. Li L., et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 2003, 24:1113-1121.
47. Li L., et al. Enhanced striatal NR2B-containing N-methyl-d-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 2004, 92:2738-2746.
48. Liu Y.F., et al. Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin. J. Biol. Chem. 2000, 275:19035-19040.
49. Liu Y., et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 2007, 27:2846-2857.
50. Liu J., et al. Calpain in the CNS: from synaptic function to neurotoxicity. Sci. Signal. 2008, 1:re1.
51. Milnerwood A.J., Raymond L.A. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J. Physiol. 2007, 585:817-831.
52. Milnerwood A.J., et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
53. Munoz J.J., et al. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. Biochem. J. 2003, 372:193-201.
54. Niwa H., et al. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108:193-199.
55. Oyama T., et al. Immunocytochemical localization of the striatal enriched protein tyrosine phosphatase in the rat striatum: a light and electron microscopic study with a complementary DNA-generated polyclonal antibody. Neuroscience 1995, 69:869-880.
56. Pacchioni A.M., Kalivas P.W. The role of AMPAR trafficking mediated by neuronal pentraxins in cocaine-induced neuroadaptations. Mol. Cell Pharmacol. 2009, 1:183-192.
57. Panov A.V., et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
58. Papadia S., Hardingham G.E. The dichotomy of NMDA receptor signaling. Neuroscientist 2007, 13:572-579.
59. Paul S., et al. NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat. Neurosci. 2003, 6:34-42.
60. Paul S., et al. The striatal-enriched protein tyrosine phosphatase gates long-term potentiation and fear memory in the lateral amygdala. Biol. Psychiatry 2007, 61:1049-1061.
61. Pelkey K.A., et al. Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron 2002, 34:127-138.
62. Perrin V., et al. Implication of the JNK pathway in a rat model of Huntington's disease. Exp. Neurol. 2009, 215:191-200.
63. Poddar R., et al. NR2B-NMDA receptor mediated modulation of the tyrosine phosphatase STEP regulates glutamate induced neuronal cell death. J. Neurochem. 2010, 115:1350-1362.
64. Roche K.W., et al. Molecular determinants of NMDA receptor internalization. Nat. Neurosci. 2001, 4:794-802.
65. Rumbaugh G., Vicini S. Distinct synaptic and extrasynaptic NMDA receptors in developing cerebellar granule neurons. J. Neurosci. 1999, 19:10603-10610.
66. Rumbaugh G., et al. SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4344-4351.
67. Sattler R., Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity. J. Mol. Med. 2000, 78:3-13.
68. Sattler R., et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999, 284:1845-1848.
69. Sawa A., et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 1999, 5:1194-1198.
70. Scappini E., et al. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase. Hum. Mol. Genet. 2007, 16:1862-1871.
71. Schwarzschild M.A., et al. Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons. J. Neurosci. 1997, 17:3455-3466.
72. Segal M., et al. Formation of dendritic spines in cultured striatal neurons depends on excitatory afferent activity. Eur. J. Neurosci. 2003, 17:2573-2585.
73. Slow E.J., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
74. Song C., et al. Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-d-aspartate receptors. J. Biol. Chem. 2003, 278:33364-33369.
75. Soriano F.X., Hardingham G.E. Compartmentalized NMDA receptor signalling to survival and death. J. Physiol. 2007, 584:381-387.
76. Soriano F.X., et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J. Neurosci. 2008, 28:10696-10710.
77. Tang T.S., et al. HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons. Eur. J. Neurosci. 2004, 20:1779-1787.
78. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2602-2607.
79. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
80. Tovar K.R., Westbrook G.L. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci. 1999, 19:4180-4188.
81. Tu W., et al. DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. Cell 2010, 140:222-234.
82. Vanhoutte P., Bading H. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr. Opin. Neurobiol. 2003, 13:366-371.
83. Vincent S.R., et al. Neurotransmitter regulation of MAP kinase signaling in striatal neurons in primary culture. Synapse 1998, 29:29-36.
84. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
85. Wang J.Q., et al. Glutamate signaling to Ras-MAPK in striatal neurons: mechanisms for inducible gene expression and plasticity. Mol. Neurobiol. 2004, 29:1-14.
86. Wang J.Q., et al. Regulation of mitogen-activated protein kinases by glutamate receptors. J. Neurochem. 2007, 100:1-11.
87. Waxman E.A., Lynch D.R. N-methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.
88. Wells G.J., Bihovsky R. Calpain inhibitors as potential treatment for stoke and other neurodegenerative diseases: recent trends and developments. Exp. Opin. Ther. Pat. 1998, 8:21.
89. Xu J., et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J. Neurosci. 2009, 29:9330-9343.
90. Zeron M.M., et al. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 2001, 17:41-53.
91. Zeron M.M., et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
92. Zeron M.M., et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci. 2004, 25:469-479.
93. 2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis. 2008, 31:80-88.